Summary
This 8-K filing from Quest Diagnostics (DGX) on February 24, 2017, announces the decision of a long-serving director, John B. Ziegler, not to seek re-election at the upcoming May 16, 2017, Annual Stockholders Meeting. Mr. Ziegler will retire from the Board of Directors at that time, concluding his current term. This development leads to a strategic reduction in the size of the Board of Directors, decreasing from 10 to 9 members effective immediately following the 2017 Annual Stockholders Meeting. Investors should note this change in board composition as it may signal adjustments in board oversight or governance strategies.
Key Highlights
- 1John B. Ziegler will retire from the Quest Diagnostics Board of Directors, effective May 16, 2017.
- 2Mr. Ziegler has chosen not to seek re-election for another term.
- 3The Board of Directors' size will be reduced from 10 to 9 members.
- 4This reduction is effective as of the 2017 Annual Stockholders Meeting.
- 5The filing is an 8-K Current Report, indicating a material event.
- 6No other officer departures or appointments are detailed in this specific filing.
Frequently Asked Questions
Mr. Ziegler has informed the company of his decision not to seek re-election at the upcoming Annual Stockholders Meeting and will retire upon the expiration of his current term.
The Board of Directors' size will be reduced from 10 to 9 members, effective after the 2017 Annual Stockholders Meeting. This indicates a potential consolidation of board oversight or governance.
No, this particular 8-K filing specifically addresses the retirement of John B. Ziegler from the Board of Directors and the subsequent reduction in the board's size. It does not detail any other officer departures, elections, or appointments.
The 2017 Annual Stockholders Meeting is scheduled to be held on May 16, 2017.